期刊文献+

胰腺癌中凋亡抑制基因Bcl-xl的研究进展 被引量:1

原文传递
导出
摘要 近年的研究显示,凋亡抑制基因Bcl-xl在胰腺癌中呈高表达。Bcl-xl高表达与胰腺癌放疗耐受,吉西他滨和TRAIL耐药及胰腺癌预后差有关。Bcl-xl小分子抑制剂和反义寡核苷酸等靶向治疗能较好地抑制胰腺癌细胞生长。此外,Bcl-xl还与导管内乳头状瘤的癌变,胰岛细胞肿瘤的侵袭转移有关。笔者综述相关文献,旨在深入研究胰腺癌中Bcl-xl表达,有利于了解其与胰腺癌的发生特别是与耐药性的关系,为胰腺癌的临床治疗提供重要理论依据。
作者 刘俊 钟福全
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2010年第9期1022-1025,共4页 China Journal of General Surgery
  • 相关文献

参考文献1

二级参考文献12

  • 1Alok A. Khorana M.D.,Ying Chuan Hu M.D., Ph.D.,Charlotte K. Ryan M.D.,Richard A. Komorowski M.D.,Galen Hostetter M.D.,Steven A. Ahrendt M.D.vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer[J].Journal of Gastrointestinal Surgery.2005(7)
  • 2H. G. Smeenk,T. C. K. Tran,J. Erdmann,C. H. J. Eijck,J. Jeekel.Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?[J].Langenbeck’s Archives of Surgery.2005(2)
  • 3Solorzano CC,Baker CH,Tsan R,Traxler P,Cohen P,Buchdunger E,Killion JJ,Fidler IJ.Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma[].Clinical Cancer Research.2001
  • 4Bruns CJ,Solorzano CC,Harbison MT,Ozawa S,Tsan R,Fan D,Abbruzzese J,Traxler P,Buchdunger E,Radinsky R,Fidler IJ.Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma[].Cancer Research.2000
  • 5Poch B,Gansauge F,Schwarz A,Seufferlein T,Schnelldorfer T,Ramadani M,Beger HG,Gansauge S.Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma: evidence for a cyclin D1-dependent cell cycle progression[].Pancreas.2001
  • 6Tobita K,Kijima H,Dowaki S,Kashiwagi H,Ohtani Y,Oida Y,Yamazaki H,Nakamura M,Ueyama Y,Tanaka M,Inokuchi S,Makuuchi H.Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis[].International Journal of Molecular Medicine.2003
  • 7Giaccone G,Gallegos Ruiz M,Le Chevalier T,Thatcher N,Smit E,Rodriguez JA,Janne P,Oulid-Aissa D,Soria JC.Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study[].Clinical Cancer Research.2006
  • 8Dragovich T,McCoy S,Fenoglio-Preiser CM,Wang J,Benedetti JK,Baker AF,Hackett CB,Urba SG,Zaner KS,Blanke CD,Abbruzzese JL.Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127[].Journal of Clinical Oncology.2006
  • 9Plestina S,Samarzija M,Plestina S,Chalfe N,Zuljevic E.[Erlotinib in non-small cell lung cancer: experience of clinical hospital for lung diseases Jordanovac][].Lijecnicki Vjesnik.2007
  • 10Thomas F,Rochaix P,Benlyazid A,Sarini J,Rives M,Lefebvre JL,Allal BC,Courbon F,Chatelut E,Delord JP.Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma[].Clinical Cancer Research.2007

共引文献4

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部